RLS Clinical Trial - Heart Rate Variability Assessment in Dialysis

Status Completed

Clinical Trial Summary

Title of the study:Heart Rate Variability Assessment in Dialysis Patients by Acupuncture Study period: 08/2019 - 07/2021 Institution: the Graduate Institute of Chinese Medical Science, China Medical University/ Changhua Christian Hospital,Taiwan Aim of the study: To investigate the effect of medical acupuncture in comparison to placebo acupuncture by heart rate variability(HRV) Design: Prospective randomized trial Intervention: Experiment group using indwelling fixed needles, N=30 ; Control group using placebo needles, N=30 Outcome measures: International RLS Rating Scale, HRV

Clinical Trial Description

RLS occurs in 3-15% of the general population and in 10-30% of patients on maintenance dialysis. End-stage renal disease, a decrease in HRV is typically found, with abnormal HRV being considered an independent risk factor for mortality.While the majority of studies show an initial improvement in symptoms, longer studies and clinical experience show that either treatment efficacy decreases with time, and/or augmentation develops: dopaminergic augmentation has been reported to be the main reason for treatment discontinuation and treatment failure in RLS/WED. The study randomly assigned to either true acupuncture treatment or placebo/sham acupuncture treatment. Each participant will undergo 12 treatments third-weekly, for a period of 4 weeks. At the end of the eighth treatment session, each participant will again fill out a IRLSRS questionnaire ,ISI and HRV test. At the end of the treatment regimen and 5weeks, participants will again fill out a IRLSRS questionnaire ,ISI and HRV test. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04356794
Study type	Interventional
Source	China Medical University, Taiwan
Contact
Status	Completed
Phase	N/A
Start date	August 23, 2019
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02633683` - An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS	Phase 4
Withdrawn	`NCT02633657` - A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS	Phase 1
Completed	`NCT05249907` - Hemodialysis Patients With Restless Legs Syndrome Used Vibration	N/A
Recruiting	`NCT02560766` - An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS	Phase 4